Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant

Shailbala Singh, Pramod N. Nehete, Guojun Yang, Hong He, Bharti Nehete, Patrick W. Hanley, Michael A Barry, K. Jagannadha Sastry

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Gene-based vaccination strategies, specifically viral vectors encoding vaccine immunogens are effective at priming strong immune responses. Mucosal routes offer practical advantages for vaccination by ease of needle-free administration, and immunogen delivery at readily accessible oral/nasal sites to efficiently induce immunity at distant gut and genital tissues. However, since mucosal tissues are inherently tolerant for induction of immune responses, incorporation of adjuvants for optimal mucosal vaccination strategies is important. We report here the effectiveness of alpha-galactosylceramide (α-GalCer), a synthetic glycolipid agonist of natural killer T (NKT) cells, as an adjuvant for enhancing immunogenicity of vaccine antigens delivered using viral vectors by mucosal routes in murine and nonhuman primate models. Significant improvement in adaptive immune responses in systemic and mucosal tissues was observed by including α-GalCer adjuvant for intranasal immunization of mice with vesicular stomatitis virus vector encoding the model antigen ovalbumin and adenoviral vectors expressing HIV env and Gag antigens. Activation of NKT cells in systemic and mucosal tissues along with significant increases in adaptive immune responses were observed in rhesus macaques immunized by intranasal and sublingual routes with protein or adenovirus vectored antigens when combined with α-GalCer adjuvant. These results support the utility of α-GalCer adjuvant for enhancing immunogenicity of mucosal vaccines delivered using viral vectors.

Original languageEnglish (US)
Pages (from-to)686-706
Number of pages21
JournalVaccines
Volume2
Issue number4
DOIs
StatePublished - Oct 24 2014

Fingerprint

Viral Vaccines
Natural Killer T-Cells
Mucous Membrane
Vaccination
Adaptive Immunity
Antigens
HIV Antigens
env Gene Products
gag Gene Products
Vesicular Stomatitis
Glycolipids
Ovalbumin
Macaca mulatta
Nose
Adenoviridae
Primates
Needles
Immunity
Immunization
Vaccines

Keywords

  • Adenovirus vector
  • Alpha-galactosylceramide
  • HIV vaccine
  • Intranasal
  • Mucosal immunity
  • NKT cells
  • Rhesus macaques
  • Vesicular stomatitis viral vector

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Singh, S., Nehete, P. N., Yang, G., He, H., Nehete, B., Hanley, P. W., ... Jagannadha Sastry, K. (2014). Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. Vaccines, 2(4), 686-706. https://doi.org/10.3390/vaccines2040686

Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. / Singh, Shailbala; Nehete, Pramod N.; Yang, Guojun; He, Hong; Nehete, Bharti; Hanley, Patrick W.; Barry, Michael A; Jagannadha Sastry, K.

In: Vaccines, Vol. 2, No. 4, 24.10.2014, p. 686-706.

Research output: Contribution to journalArticle

Singh, S, Nehete, PN, Yang, G, He, H, Nehete, B, Hanley, PW, Barry, MA & Jagannadha Sastry, K 2014, 'Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant', Vaccines, vol. 2, no. 4, pp. 686-706. https://doi.org/10.3390/vaccines2040686
Singh, Shailbala ; Nehete, Pramod N. ; Yang, Guojun ; He, Hong ; Nehete, Bharti ; Hanley, Patrick W. ; Barry, Michael A ; Jagannadha Sastry, K. / Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. In: Vaccines. 2014 ; Vol. 2, No. 4. pp. 686-706.
@article{dfcd6ff8b091485cb04c498abfacc8f6,
title = "Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant",
abstract = "Gene-based vaccination strategies, specifically viral vectors encoding vaccine immunogens are effective at priming strong immune responses. Mucosal routes offer practical advantages for vaccination by ease of needle-free administration, and immunogen delivery at readily accessible oral/nasal sites to efficiently induce immunity at distant gut and genital tissues. However, since mucosal tissues are inherently tolerant for induction of immune responses, incorporation of adjuvants for optimal mucosal vaccination strategies is important. We report here the effectiveness of alpha-galactosylceramide (α-GalCer), a synthetic glycolipid agonist of natural killer T (NKT) cells, as an adjuvant for enhancing immunogenicity of vaccine antigens delivered using viral vectors by mucosal routes in murine and nonhuman primate models. Significant improvement in adaptive immune responses in systemic and mucosal tissues was observed by including α-GalCer adjuvant for intranasal immunization of mice with vesicular stomatitis virus vector encoding the model antigen ovalbumin and adenoviral vectors expressing HIV env and Gag antigens. Activation of NKT cells in systemic and mucosal tissues along with significant increases in adaptive immune responses were observed in rhesus macaques immunized by intranasal and sublingual routes with protein or adenovirus vectored antigens when combined with α-GalCer adjuvant. These results support the utility of α-GalCer adjuvant for enhancing immunogenicity of mucosal vaccines delivered using viral vectors.",
keywords = "Adenovirus vector, Alpha-galactosylceramide, HIV vaccine, Intranasal, Mucosal immunity, NKT cells, Rhesus macaques, Vesicular stomatitis viral vector",
author = "Shailbala Singh and Nehete, {Pramod N.} and Guojun Yang and Hong He and Bharti Nehete and Hanley, {Patrick W.} and Barry, {Michael A} and {Jagannadha Sastry}, K.",
year = "2014",
month = "10",
day = "24",
doi = "10.3390/vaccines2040686",
language = "English (US)",
volume = "2",
pages = "686--706",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant

AU - Singh, Shailbala

AU - Nehete, Pramod N.

AU - Yang, Guojun

AU - He, Hong

AU - Nehete, Bharti

AU - Hanley, Patrick W.

AU - Barry, Michael A

AU - Jagannadha Sastry, K.

PY - 2014/10/24

Y1 - 2014/10/24

N2 - Gene-based vaccination strategies, specifically viral vectors encoding vaccine immunogens are effective at priming strong immune responses. Mucosal routes offer practical advantages for vaccination by ease of needle-free administration, and immunogen delivery at readily accessible oral/nasal sites to efficiently induce immunity at distant gut and genital tissues. However, since mucosal tissues are inherently tolerant for induction of immune responses, incorporation of adjuvants for optimal mucosal vaccination strategies is important. We report here the effectiveness of alpha-galactosylceramide (α-GalCer), a synthetic glycolipid agonist of natural killer T (NKT) cells, as an adjuvant for enhancing immunogenicity of vaccine antigens delivered using viral vectors by mucosal routes in murine and nonhuman primate models. Significant improvement in adaptive immune responses in systemic and mucosal tissues was observed by including α-GalCer adjuvant for intranasal immunization of mice with vesicular stomatitis virus vector encoding the model antigen ovalbumin and adenoviral vectors expressing HIV env and Gag antigens. Activation of NKT cells in systemic and mucosal tissues along with significant increases in adaptive immune responses were observed in rhesus macaques immunized by intranasal and sublingual routes with protein or adenovirus vectored antigens when combined with α-GalCer adjuvant. These results support the utility of α-GalCer adjuvant for enhancing immunogenicity of mucosal vaccines delivered using viral vectors.

AB - Gene-based vaccination strategies, specifically viral vectors encoding vaccine immunogens are effective at priming strong immune responses. Mucosal routes offer practical advantages for vaccination by ease of needle-free administration, and immunogen delivery at readily accessible oral/nasal sites to efficiently induce immunity at distant gut and genital tissues. However, since mucosal tissues are inherently tolerant for induction of immune responses, incorporation of adjuvants for optimal mucosal vaccination strategies is important. We report here the effectiveness of alpha-galactosylceramide (α-GalCer), a synthetic glycolipid agonist of natural killer T (NKT) cells, as an adjuvant for enhancing immunogenicity of vaccine antigens delivered using viral vectors by mucosal routes in murine and nonhuman primate models. Significant improvement in adaptive immune responses in systemic and mucosal tissues was observed by including α-GalCer adjuvant for intranasal immunization of mice with vesicular stomatitis virus vector encoding the model antigen ovalbumin and adenoviral vectors expressing HIV env and Gag antigens. Activation of NKT cells in systemic and mucosal tissues along with significant increases in adaptive immune responses were observed in rhesus macaques immunized by intranasal and sublingual routes with protein or adenovirus vectored antigens when combined with α-GalCer adjuvant. These results support the utility of α-GalCer adjuvant for enhancing immunogenicity of mucosal vaccines delivered using viral vectors.

KW - Adenovirus vector

KW - Alpha-galactosylceramide

KW - HIV vaccine

KW - Intranasal

KW - Mucosal immunity

KW - NKT cells

KW - Rhesus macaques

KW - Vesicular stomatitis viral vector

UR - http://www.scopus.com/inward/record.url?scp=84908237850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908237850&partnerID=8YFLogxK

U2 - 10.3390/vaccines2040686

DO - 10.3390/vaccines2040686

M3 - Article

AN - SCOPUS:84908237850

VL - 2

SP - 686

EP - 706

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 4

ER -